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Abstract
Background: The mortality following blood stream infection (BSI) and risk of subsequent BSI in relation to dialysis
modality, vascular access, and other potential risk factors has received relatively little attention. Consequently, we
assessed these matters in a retrospective cohort study, by use of the Danish nation-wide registries.
Methods: Patients more than 17 years of age, who initiated dialysis between 1.1.2010 and 1.1.2014, were grouped
according to their dialysis modality and vascular access. Survival was modeled in time-dependent Cox proportional
hazard analyses. Potential risk factors confined by a modified Charlson comorbidity index (MCCI), were subsequently
assessed in stepwise selection models.
Results: At baseline, 764 patients received peritoneal dialysis (PD), and 434, 479, and 782 hemodialysis (HD) patients
were dialyzed by use of arteriovenous fistulas (AVFs), tunneled catheters (TCs), and non-tunneled catheters (NTCs),
respectively. We identified 1069 BSIs with an overall incidence rate of 17.7 episodes per 100 person years, and 216
BSIs occurred more than one time in the same patient. HRs of post BSI mortality relative to PD were 3.20 (95% CI
1.86–5.50; p < 0.001) with NTCs; whereas no associations were found for AVF and TC. The risk of subsequent BSIs
was higher with NTCs [HR 2.29 (95% CI 1.09–4.82), p = 0.030], and no significant difference was found for AVF
and TC, in relation to PD. There was an increased risk of both outcomes with TC relative to AVF [death: 1.57
(95% CI 1.07–2.29, P < 0.021); BSI: 1.78 (95% CI 1.13–2.83, P < 0.014], and risk of death was reduced in patients
who changed to AVF after first-time BSI. The MCCI was significantly associated with the risk of subsequent BSI
and post BSI death; however, only some of the variables contained in the index were found to be significant
risk predictors when analyzed in the fitted model.
Conclusions: While NTC was the most predominant risk factor for subsequent BSI and post BSI mortality, AVF
appeared protective.
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Background
Approximately 10% of the total global population is
affected by chronic kidney disease (CKD), and over
two million people receive dialysis worldwide, not-
withstanding that this amount only represents a frac-
tion (10%) of the people who need renal replacement
therapy (RRT) to stay alive [1, 2]. Blood stream infection
(BSI) is a significant threat among patients receiving RRT
and remains the second most frequent cause of death in
this population [3, 4]. Thus, the risk of BSI was recently
found to be 28 times greater in patients receiving
hemodialysis (HD) than in a matched population without
kidney disease [5].
There are several contributing factors to this high
frequency of BSI, e.g., advanced comorbidity, immune
dysfunction caused by uremia, and frequent disrup-
tions of the natural skin barrier [6–8]. Some of these
factors such as RRT modality and vascular access type
can be directly modified by health care professionals
and thus supply a potential opportunity for interven-
tions that eventually can reduce the risk of BSI and
subsequent post BSI mortality. In this regard, patients
receiving peritoneal dialysis (PD) or HD via non-
catheter-based access types, i.e., arteriovenous fistulas
(AVFs) and arteriovenous grafts (AVGs), have a much
lower incidence of BSI than patients receiving HD by
use of central venous catheters, i.e., tunneled central
venous HD catheters (TCs) and non-tunneled cathe-
ters (NTCs), respectively, in which the latter has been
associated with the highest incidence rates [7, 9–15].
Accordingly, such risk factors that are susceptible for
improvements deserve study.
Numerous studies have examined the epidemiology of
BSI, particularly in HD patients. However, the mortality
following BSI has until now received relatively little
attention, and there has been a preferential focus on
infections caused by Staphylococcus aureus (S. aureus)
[7, 16–19]. Large scale studies are generally hampered
by the lack of specific patient data, while small,
center-based studies have insufficient statistical power.
The establishment in 2010 of the Danish Microbiology
Database (MiBa) now allows detailed examination of the
epidemiology, potential risk factors, and prognosis of
BSI amongst patients receiving dialysis. Consequently, in
the current study, using Danish nationwide registries, we
aim to describe the incidence of BSI and the resulting
causal microbial species, in an incident cohort of RRT
patients, with specific consideration of HD and PD, as
well as subsequent access modalities of HD, i.e., TC,
NTC, and AVF, respectively. Furthermore, we will exam-
ine the risk of subsequent BSI episodes and post BSI
mortality among patients in HD, with explicit focus on
HD access modality and risk factors confined in a modi-
fied Charlson comorbidy index.
Methods
Patients and registries
This study was prepared as a retrospective, epidemio-
logic cohort study concerning all patients more than 17
years of age, who initiated dialysis (PD or HD) between
1.1.2010 and 1.1.2014, using the Danish Nephrology
Registry (DNR), MiBa, and the Danish nationwide
administrative registries as data source.
All citizens in Denmark have a unique personal identi-
fication number, which allows for individual-level linkage
of information from the applied registries. DNR was
established in 1990 and contains comprehensive data
concerning all patients receiving RRT [20]. MiBa con-
tains nationwide data on microbiological diagnoses, in-
cluding all positive blood cultures identified in Denmark
since 2010 [21]. Since 1978, information on all admis-
sions to Danish hospitals, according to the international
classification code (ICD) and the Nordic classification of
surgical procedures (NCSP), respectively, have been reg-
istered in the National Patients Registry [22, 23]. Infor-
mation on age, sex, renal diagnosis, date of referral to a
nephrology department, date of dialysis initiation, access
type at first access, and date of RRT modality changes
(HD, PD or transplantation (RT)) was obtained from the
DNR. This registry also supplied information on initial
and subsequent dialysis modality and access type, i.e.,
PD, AVF, NTC and TC. AVGs are not regularly used in
Denmark. Date of all surgical TC and AVF procedures,
changes from one vascular access type to another, and
information on comorbidity at the day of dialysis initi-
ation were obtained from the National Patient Registry.
The primary cause of death was obtained from the DNR.
We applied a modified Charlson comorbidity index
(MCCI), in which each of the following comorbidities
was assigned one index point: diabetes (DM), heart fail-
ure, ischemic heart disease, peripheral vascular disease,
ischemic/hemorrhagic/neurologic CNS disease, chronic
obstructive pulmonary disease (COPD), collagenoses,
gastric ulcer, liver disease, and cancer (all types, includ-
ing leukemia). All patients were automatically allocated
one index point for CKD. The index was further divided
in three levels, i.e. MCCI = 1, MCCI = 2–3 and MCCI >
3 for use in the main statistical model.
The date and result of all positive cultures for the
included patients were obtained from MiBa. In specific
situations with unreproducible positive cultivations of
e.g. opportunistic skin-associated low virulence microor-
ganisms and lack of clinically signs of BSI, positive
cultures were registered as ‘possible contamination’ by
the corresponding microbiologic departments. Positive
cultures identified before the date of first dialysis were
excluded. Multiple positive cultures on the same day were
classified as polymicrobial. Multiple positive cultures within
a 7-day period were regarded as one BSI episode, with the
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first positive culture being registered as the causative agent.
Bacterial diagnoses were classified into 13 major groups for
analysis: S. aureus, Coagulase Negative Staphylococci
(CNS), Unspecified Staphylococci (where only the genus
was reported, and not the species), Streptococci, Entero-
cocci, Other gram-positive bacteria, Escherichia coli (E.
coli), Enterobacter, Klebsiella pneumoniae (klebsiella),
Pseudomonas aeruginosa (pseudomonas), Other gram-
negative bacteria, Fungi, and Other (where a positive blood
cultivation was reported without genus or species). In the
current study, CNS was defined as the ability of the
staphylococcus species to coagulate plasma, which basically
included all other Staphylococci than S. aureus. For a full
presentation of the microorganisms included in each group,
please see Additional file 1.
PermCath catheters are the standard cuffed catheters
of choice in Denmark. Routinely, TCs are maintained by
use of aseptic techniques applied by adequately trained
personnel. In the setting of BSI, TCs are in general tem-
porarily removed in favor of a NTC, and a new TC is
inserted when the infection has resolved. In the absence
infectious involvement of the tunnel, TCs may be
renewed by guidewire catheter exchange, and in some
settings, the TC is left in place, depending on infection
severity, microbiology, and vascular accessibility, how-
ever, antibiotic lock solutions are not commonplace in
Denmark. In terms of AVFs, these are usually allowed a
ripening period of approximately 6 weeks before usage,
and buttonhole needling is the most frequently applied
method for cannulation; although, rope ladder needling
may be preferred in some departments. Overall, to cover
a wide spectrum of both gram-positive and gram-nega-
tive causative organisms in vascular access-related BSIs,
and due to the relatively low occurrence of methicillin
resistant Staphylococcus aureus in Denmark, a
broad-spectrum beta-lactam antibiotic agent is utilized
as first choice empirical treatment, e.g., piperacillin with
tazobactam or cefuroxime. The antibiotic therapy is
subsequently tailored according to the microbiologic
cultivation results.
Statistics
Crude incidence rates (IRs) for each study outcome per
100 person-years were calculated for patients receiving
PD and HD, as well as each HD vascular access type.
Differences in baseline characteristics were analyzed
with Chi-square test for categorical covariates and
Student’s t-test or the non-parametric Kruskal-Wallis
and Mann-Whitney tests for continuous variables, re-
spectively. Time dependent Cox proportional hazard
models were used to model survival and other end-
points, and outcomes were expressed as hazard ratios
(HRs). Patients entered the model at the day of dialysis
initiation, and the cohort was followed until occurrence
of a study outcome or until 1.1.2015. The following out-
comes were assessed in different models: BSI, all-cause
mortality, subsequent BSIs (after first-time BSI) and post
BSI mortality. In analyses of all-cause mortality and
first-time BSI, each observation was split at any change
in dialysis modality or vascular access, so that these vari-
ables could change time-dependently. In analyses on the
effect of first-time BSI in risk of all-cause mortality as
compared to patients without BSI, each observation was
also split at the day the causal microorganism was
isolated, to avoid immortal time bias. In the absence of
registered TC or AVF creation, all NTCs were censored
90 days after initiation. In addition, all analyses were ad-
justed for age, sex, calendar year, MCCI, and Gram stain.
The latter was only included in consideration of patients
who have had a first-time BSI. Results were tested in
sensitivity analyses where all covariates were included at
baseline. Furthermore, we modeled the risk of all-cause
mortality and first-time BSI in baseline analyses where a
60-day qualifying period, i.e., the date of dialysis initi-
ation (index date) plus 60 days, was added to avoid an
anticipated high risk of complications in close temporal
proximity to RRT initiation. As we did not have infor-
mation on the specific infectious focus preceding a BSI,
we performed a baseline subgroup analysis of patients
with first-time BSI caused by S. aureus, which are most
likely to be caused by the vascular/peritoneal access.
Also, we investigated the effect of vascular access change
subsequent to first-time BSI on risk of post BSI mortal-
ity. Time-dependent analyses were censored at the day
of RT, and change of modality. Baseline analyses were
additionally censored at the day of change in vascular
access. Finally, each variable confined by the MCCI was
evaluated in a stepwise selection model with alternating
forward selection and backward elimination, i.e., only
variables with a univariate P value < 0.25 were allowed
to be tested further in the stepwise model, and only
variables that contributed with a P value of < 0.15 were
contained in the fitted model. The proportional hazard
assumption, linearity of continuous variables and
absence of interaction between variables were fulfilled if
not otherwise stated. A two-sided P value of 0.05 or less
was considered significant. P values > 0.10 are denoted in
the text as ‘not significant’ (NS) unless stated otherwise.
Analyses and data management were performed in SAS
version 9.4 (SAS Institute Inc. Cary, North Carolina) and
R version 3.3.3 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Population
In the period January 2010–January 2014, 2646 incident
men and women more than 17 years of age, receiving
RRT were identified from DNR, of whom 1742 received
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HD, 764 PD and 140 underwent RT as their first
registered RRT modality, leaving 2506 patient ready for
inclusion. At baseline, 434, 479, and 782 HD patients
were dialyzed by use of AVFs, TCs, and NTCs, respect-
ively. Forty-seven patients did not have their initial HD
access registered. Patients with missing data concerning
initial access did not differ significantly from the other
patients (data not shown). During follow up, 1027
patients died of which 366 occurred after BSI, 303
underwent RT, and 124 regained some degree of native
renal function. The mean age at baseline in the total
study population was 64.8 ± 15.2 years, with an overall
overweight of male gender (65.4%). In general, patients
who initially received a NTC were of the same age;
however, they were burdened with excess comorbidity as
compared to patients with AVF, TC and PD. Conversely,
the group of patients who started on PD were slightly
younger, and presented with a lower percentage of pa-
tients classified with high MCCI scores. Other baseline
characteristics are shown in Table 1. Mean follow up for
the total study population was 1.7 ± 1.4 (median 1.5,
interquartile range (IQR) 0.3–2.7) years.
We identified 1069 episodes of bacteremia in 784
patients corresponding to an overall IR of 17.7 episodes
per 100 person years. A total of 169, 33, and 14
bacteremia episodes occurred two, three and more than
three times in the same person. In 71 cases, the putative
causative microorganism was registered as ‘possible con-
tamination’ and 30 cases were classified as polymicrobial.
With S. aureus (32.1%) and E. coli (13.3%) being the pri-
mary individual isolates, the overall Gram-positive and
Gram-negative bacteria accounted for 68.0 and 29.7% of
the cultured microorganisms, respectively. E. coli was
isolated in 19.5% of the bacteremia episodes among
patients on PD, and in 11.8% among those on HD.
Conversely, S. aureus appeared more frequently among
HD patients as compared with PD (35.1% vs. 20.1%). As
shown in Fig. 1, the composition of microorganisms in
the first encountered bacteremia differed considerably
from what was isolated after more than two bloodstream
infections, with a slight reduction in Gram positive mi-
croorganisms. Where first-time bloodstream infections
were dominated by S. aureus and E. coli; fungi, other
Staphylococcus species, Enterococci, Klebsiella and
Pseudomonas were significantly more prevalent among
patients with more than two blood stream infections
(Fig. 1). The overall distribution of the 13 pre-specified
microbiologic groups for first-time BSI according to the
vascular access modality as well as PD are shown in Table 1.
Survival analyses
Crude IRs for first-time BSI and all-cause mortality are
shown in Table 2. Censored IRs are listed in Figs. 2 and 3.
In the fully adjusted time-dependent Cox proportional
hazard analyses we found an increased risk of BSI for
patients receiving HD by use of AVF [HR 1.35 (95% CI
1.10–1.67), P = 0.005], TC [HR 2.25 (95% CI 1.74–2.90),
P < 0.001], and NTC [HR 6.87 (95% CI 5.57–8.48), P <
0.001] relative to patients receiving PD (Fig. 3). Also, there
was an increased risk of all-cause mortality associated with
TC and NTC with HRs of 1.42 (95% CI 1.14–1.77, P =
0.002) and 5.22 (95% CI 4.36–6.25, P < 0.001), respectively.
However, there was no significant difference in risk of
all-cause mortality for AVF [HR 0.86 (95% CI 0.72–1.03),
NS] relative to PD (Fig. 3). Comparable results were found
in baseline analyses where patients entered the model at
the date of dialysis initiation, and when a 60-day qualifying
period was applied (Additional file 2).
In time-dependent Cox analyses modeled to examine
the risk of death after first-time BSI as compared to all
patients without BSI, regardless of dialysis and vascular ac-
cess type, we found a significantly increased risk of death
associated with all modalities with HRs of 2.72 (95% CI
1.70–4.37, P < 0.001), 1.99 (95% CI 1.62–2.43, P < 0.001),
2.92 (95% CI 2.12–4.03, P < 0.001), and 6.44 (95% CI
5.15–8.08, P < 0.001) for PD, AVF, TC and NTC, respect-
ively (Fig. 2). Confining the analysis to only include pa-
tients after their first-time BSI with PD as reference, there
was no significant difference between AVF and TC relative
to PD; whereas NTC remained significantly associated
with a marked increase in risk of death (Fig. 3). Compar-
able results were found in analyses based on baseline
variables, as well as in the subgroup analyses that only in-
cluded patients with a first-time BSI caused by S. aureus
(Additional file 2). Also, the risk of subsequent BSI
episodes was significantly higher in HD patients who
encountered their first BSI with a NTC [HR 2.29 (95% CI
1.09–4.82), p = 0.030], whereas no significant difference
was found for patients with AVF [HR 0.94 (95% CI 0.46–
1.93), NS] and TC [HR 1.68 (95% CI 0.77–3.70), NS]. In
post hoc analyses, HRs for post BSI mortality and subse-
quent BSI with TCs, using AVF as reference, were 1.57
(95% CI 1.07–2.29, P < 0.021) and 1.78 (95% CI 1.13–2.83,
P < 0.014), respectively. Finally, we found an overall de-
creased risk of all-cause mortality associated with patients
who changed their vascular access in the period after first
BSI episode [HR 0.61 (95% CI 0.47–0.79), P < 0.001];
however, this association was not evident in a subgroup
analysis restricted to those who did not receive an AVF
[HR 0.73 (95% CI 0.41–1.23), NS]. Estimates regarding the
other included covariates in the main time-dependent
Cox models, and from the two-step fitted model covering
each of the covariates included in the modified comorbid-
ity score, are shown in Tables 3 and 4, respectively.
Discussion
In the current register-based retrospective cohort study,
we investigated the incidence and risk of BSI including
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Table 1 Baseline characteristics of incident patients receiving renal replacement therapy during 2010–2013 with specific
consideration on peritoneal dialysis and hemodialysis vascular access type
PD AVF TC NTC P value
N 764 434 479 782
Male (%) 509 (66.6) 289 (66.6) 296 (61.8) 514 (65.7) NS
Age (mean (SD)) 63.3 (14.8) 65.9 (14.0) 65.0 (16.4) 65.5 (15.3) 0.025
MCCI (%) < 0.001
2 225 (29.5) 92 (21.2) 84 (17.5) 119 (15.2)
3 127 (16.6) 77 (17.7) 66 (13.8) 108 (13.8)
4 173 (22.6) 85 (19.6) 96 (20.0) 134 (17.1)
5 103 (13.5) 66 (15.2) 93 (19.4) 150 (19.2)
> 5 133 (17.4) 114 (26.3) 138 (28.8) 265 (33.9)
Missing 3 (0.4) 0 (0.0) 2 (0.4) 6 (0.8)
Average MCCI 3.9 (1.8) 4.4 (2.1) 4.7 (2.2) 4.9 (2.3)
Median (IQR) 4 (2–5) 4 (3–6) 4 (3–6) 5 (3–6)
Renal diagnosis (%) < 0.001
CIN 25 (3.3) 20 (4.6) 18 (3.8) 31 (4.0)
DM 185 (24.2) 111 (25.6) 134 (28.0) 202 (25.8)
GN 90 (11.8) 26 (6.0) 46 (9.6) 60 (7.7)
Hypertension 103 (13.5) 71 (16.4) 56 (11.7) 96 (12.3)
PKD 58 (7.6) 48 (11.1) 25 (5.2) 19 (2.4)
Other 74 (9.7) 55 (12.7) 86 (18.0) 194 (24.8)
Unknown 229 (30.0) 103 (23.7) 114 (23.8) 180 (23.0)
BSI episodes NS
1 123 (79.9) 90 (73.2) 119 (68.4) 224 (70.9)
2 28 (18.2) 23 (18.7) 38 (21.8) 76 (24.1)
3 1 (0.6) 8 (6.5) 14 (8.0) 10 (3.2)
4 1 (0.6) 1 (0.8) 2 (1.1) 3 (0.9)
5 1 (0.6) 1 (0.8) 1 (0.6) 2 (0.6)
6 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Microorganisms (%) NS
S. aureus 31 (20.1) 42 (34.1) 70 (40.2) 102 (32.3)
E. coli 30 (19.5) 15 (12.2) 15 (8.6) 42 (13.3)
Enterococci 11 (7.1) 7 (5.7) 10 (5.7) 28 (8.9)
Enterobacter 5 (3.2) 5 (4.1 14 (8.0) 9 (2.8)
Other gram-neg 12 (7.8) 4 (3.3) 9 (5.2) 17 (5.4)
Other gram-pos 4 (2.6) 7 (5.7) 4 (2.3) 15 (4.7)
Klebsiella pneumoniae 8 (5.2) 10 (8.1) 5 (2.9) 16 (5.1)
Pseudomonas aeruginosa 3 (1.9) 1 (0.8) 6 (3.4) 7 (2.2)
CNSa 22 (14.3) 13 (10.6) 15 (8.6) 40 (12.7)
Unspecified staphylococcib 15 (9.7) 11 (8.9) 12 (6.9) 25 (7.9)
Streptococci 10 (6.5) 6 (4.9) 9 (5.2) 12 (3.8)
Fungi 3 (1.9) 0 (0.0) 2 (1.1) 2 (0.6)
Otherb 0 (0.0) 2 (1.6) 3 (1.7) 1 (0.3)
PD peritoneal dialysis, AVF arteriovenous fistula, TC tunneled catheter, NTC non-tunneled catheter, MCCI Modified Charlson comorbidity index, CIN chronic
interstitial nephritis, DM diabetes mellitus, GN glomerulonephritis, PKD polycystic kidney disease, NS not significant, CNS Coagulase Negative Staphylococci.
For a full disclosure of microorganisms included in each of the 13 microbial groups outlined in this table, see Additional file 1. The P value is calculated as the
overall difference between groups or the overall difference of distribution between groups
a Defined as the ability of the organism to coagulate plasma, i.e. all other Staphylococci than S. aureus
b Only the genus was reported, not the species
c A positive blood cultivation was reported without genus or species
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the causal microbial species, as well as the risk of
all-cause mortality with and without consideration of
first-time BSI, in patients receiving PD and HD, respect-
ively, with explicit focus on HD access modality and
potential causal risk factors defined by a modified co-
morbidity index. Gram positive bacteria were the most
prevalent causal microorganisms among patients with
first-time BSI in the total study population. However,
while S. aureus dominated the isolates from HD pa-
tients, E. coli was more frequently isolated in patients on
PD. Also, we observed an increasing growth of putative
antibiotic-resistant, biofilm producing microorganisms
among patients with more than one BSI episode. There
was an increased risk of BSI associated with HD as com-
pared to PD, and the highest risks were associated with
catheter-based vascular access modalities, i.e., NTC and
TC, listed in order of priority. Furthermore, the highest
risk of all-cause mortality was associated with NTC
followed by TC, and there was no difference between
PD and AVF. The overall risk death after first-time BSI
was markedly increased as compared to patients without
BSI, however most importantly, while the risk of death
Fig. 1 Distribution of causal microbiologic isolates at first-time BSI (a) and after more than two BSI episodes (b). CNS: coagulase negative
staphylococci. The P-value for overall difference in distribution of microbiologic isolates between a and b were < 0.001
Table 2 Crude incidence rates for first-time blood stream infection and all-cause mortality
Modality/Access N Risk timea IRb Interval N Risk timea IRb Interval
Blood stream infection All-cause mortality
Total 784 44.2 17.7 16.5–19.0 1027 44.2 23.2 21.8–24.7
PD 154 16.3 9.43 8.05–11.0 227 16.3 13.9 12.2–15.8
HD 630 27.9 22.6 20.9–24.4 800 27.9 28.7 26.7–30.7
- AVF 123 9.78 12.6 10.5–15.0 153 9.78 15.6 13.3–18.3
- TC 174 9.40 18.5 16.0–21.5 219 9.40 23.3 20.4–26.6
- NTC 316 7.9 39.8 35.6–44.4 407 7.9 51.2 46.5–56.46
PD peritoneal dialysis, HD hemodialysis, AVF arteriovenous fistula, TC tunneled catheter, NTC non-tunneled catheter, IR incidence ratio. a 102 patient years. b 1/100
patient years
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and BSI remained clearly increased with NTCs in all
conducted analyses, there was no significant difference
in risk of post BSI mortality between AVF and TC rela-
tive to PD, although the trend towards a better outcome
for patients with AVF remained. These findings were
supported by the absence of difference between the PD
and AVF in risk of subsequent BSI episodes, a significant
increased risk associated with TC relative to AVF for
both outcomes after first-time BSI, as well as a reduced
risk of post BSI mortality in patients who changed their
Fig. 2 Risk of post BSI mortality in patients with a first-time BSI. Results from the adjusted time-dependent Cox proportional hazard analyses. IR:
Incidence rate per 100 patient-years; HR: Hazard ratio for the risk of death after first time BSI. Patients without BSI are used as reference. AVF:
arteriovenous fistula; TC: tunneled catheter; NTC: non-tunneled catheter; BSI: blood stream infection. Error bars illustrate 95% confidence intervals
Fig. 3 Risk of blood stream infection (BSI) and death in the total study population and after first-time BSI. Results from the adjusted time-
dependent Cox proportional hazard analyses. IR: Incidence rate per 100 patient-years; HR: Hazard ratio for the risk of BSI and all-cause mortality, as
well as subsequent BSI episodes and post BSI mortality after first-time BSI. Patients receiving peritoneal dialysis (PD) are used as reference. AVF:
arteriovenous fistula; TC: tunneled catheter; NTC: non-tunneled catheter; BSI: blood stream infection. Error bars illustrate 95% confidence intervals
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vascular access to AVF. Finally, older age was a sig-
nificant predictor of post BSI mortality but not for
subsequent BSI, and the modified comorbidity index
was well correlated with both outcomes, although
only some of the individual comorbidities confined by
the applied comorbidity index were found to be
significant in the fitted statistical model. To our
knowledge, we are the first to investigate the risk and
risk factors of subsequent BSI and post BSI mortality
among the different types of vascular access modal-
ities in relation to PD.
Numerous of studies have investigated the epidemi-
ology of BSI, and as supported by the current study, it
is generally recognized, that the risk of BSI is markedly
increased in HD patients relative to PD, although the
overall infection-related hospitalization may be higher
with the latter [7, 9–13]. Also, the vascular access type
has a major impact on risk of BSI, in which the
catheter-based modalities, and in particular NTCs, are
found with the highest risk [14, 15]. Although there has
been a preferential focus in S. aureus bacteremia, the
microbiologic fauna in first-time BSIs is comprehen-
sively studied, and the majority of these investigations
are supported by our findings, with most isolates being
Gram positive (approximate 60%), S. aureus being the
most frequently isolated causal microorganism, and a
relative higher incidence of E. coli bacteremia among PD
patients [5, 12, 15]. It is also evident, that the risk of
all-cause mortality is increased with catheter-based HD
modalities; however, as suggested by others [24], we found
no significant difference between PD and AVF in risk of
all-cause mortality. In fact, there was a trend towards a
reduced mortality risk with the latter; and patients who
changed their vascular access to AVF after a first-time BSI
had a reduced risk of death. Accordingly, as the risk of
BSI was higher with AVF relative to PD, these findings
suggest that the risk of death among patients with an AVF
is less influenced by BSIs as compared to catheter-based
RRT modalities, including PD. To our knowledge, there
are no data available to differentiate between the specific
causes of post BSI mortality with AVF and PD. However,
the risk of other dialysis-related infections and subsequent
cardiovascular death may be increased in patients on PD,
and the risk of metastatic infections in S. aureus
bacteremia, e.g., endocarditis, osteomyelitis, CNS abscess
etc., with subsequent death is markedly increased with
Table 3 Risk of blood stream infections and mortality associated with covariates included in the time-dependent cox proportional
hazard models
Model entry variable HR (CI) P value HR (CI) P value
Blood stream infection Mortality
RRT initiation AVFa 1.35 (1.20–1.67) 0.005 0.86 (0.72–1.03) NS
TCa 2.25 (1.74–2.90) < 0.001 1.42 (1.14–1.77) 0.002
NTCa 6.87(5.53-8.48) < 0.001 5.22 (4.36–6.25) < 0.001
Sex 1.10 (0.95–1.23) NS 1.02 (0.89–1.16) NS
Age 50–59b 1.19 (0.92–1.54) NS 1.55 (1.10–2.18) 0.012
Age 60–69b 1.05 (0.83–1.32) NS 2.14 (1.59–2.90) < 0.001
Age > 70b 0.91 (0.73–1.13) NS 3.71 (2.79–4.93) < 0.001
MCCI (2, 3)c 0.87 (0.71–1.08) NS 1.75 (1.36–2.24) < 0.001
MCCI (> 3)c 1.14 (0.94–1.40) NS 2.76 (2.18–3.51) < 0.001
Post BSI AVFa 0.94 (0.46–1.93) NS 0.83 (0.50–1.39) NS
TCa 1.68 (0.77–3.70) NS 1.30 (0.72–2.34) NS
NTCa 2.29 (1.09–4.82) 0.030 3.20 (1.86–5.50) < 0.001
Sex 1.14 (0.81–1.60) NS 1.07 (0.83–1.38) NS
Age 50–59b 1.47 (0.85–2.56) NS 1.53 (0.82–2.86) NS
Age 60–69b 1.25 (0.75–2.10) NS 2.56 (1.50–4.37) < 0.001
Age > 70c 1.35 (0.81–2.23) NS 5.41 (3.26–9.00) < 0.001
MCCI (2, 3)c 1.70 (0.94–3.07) 0.081 1.96 (1.20–3.20) 0.008
MCCI (> 3)c 2.99 (1.72–5.19) < 0.001 2.99 (1.88–4.74) < 0.001
Gram + 0.89 (0.62–1.27) NS 0.77 (0.59–0.99) 0.044
HD hemodialysis, AVF arteriovenous fistula, TC tunneled catheter, NTC non-tunneled catheter, MCCI modified Charlson comorbidity index, NS not significant, HR
hazard ratio, CI confidence interval
a Analyzed as a four-leveled variable with peritoneal dialysis as reference
b Analyzed as a four-leveled variable with ‘age < 50 years’ as reference
c Analyzed as a three-leveled variable with ‘MCCI = 1’ as reference
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TCs [11, 17, 25, 26]. Consequently, in addition to the
relatively low IRs of BSI, AVF may be a favorable choice
due to an overall better prognosis after BSI.
Although the trend towards an incremental relation-
ship between the included dialysis modalities as well as
vascular access types on risk of BSI and death remains
Table 4 Univariate and fitted estimates of covariates included in the time-dependent Cox proportional hazard models on the risk of
blood stream infection and mortality, including variables confined by the modified comorbidity index
Model entry Variable Univariate HR P Value Fitted HR P value Univariate HR P Value Fitted HR P Value
Blood stream infection Mortality
RRT initiation AVF* 1.29 0.016 1.37 0.003 0.97 0.745 0.90 0.223***
TC* 2.29 < 0.001 2.25 < 0.001 1.75 < 0.001 1.48 < 0.001
NTC* 7.53 < 0.001 6.92 < 0.001 6.20 < 0.001 5.19 < 0.001
Sex 1.06 NS – – 0.98 NS – –
Age 50–59** 1.14 NS – – 1.75 0.001 1.65 0.004
Age 60–69** 1.05 NS – – 2.56 < 0.001 2.20 < 0.001
Age > 70** 1.01 NS – – 4.77 < 0.001 3.70 < 0.001
Heart Failure 1.30 0.003 – – 2.05 < 0.001 1.34 < 0.001
AMI 1.20 0.068 – – 1.92 < 0.001 1.23 0.013
Vascular 1.13 NS – – 1.78 < 0.001 1.25 0.002
CNS disease 0.96 NS – – 1.45 < 0.001 1.14 0.079
COPD 1.18 0.094 – – 1.79 < 0.001 1.34 < 0.001
Collagenoses 0.98 NS – – 1.02 NS 0.84 0.122
Peptic ulcer 1.25 0.039 – – 1.48 < 0.001 – –
Liver disease 1.76 < 0.001 1.52 0.005 1.36 0.028 1.41 0.016
Cancer 1.18 0.072 – – 1.81 < 0.001 1.35 < 0.001
Diabetes 1.34 < 0.001 1.30 < 0.001 1.30 < 0.001 1.22 0.003
Post BSI AVF* 1.14 0.720 0.98 0.947 0.76 0.252 0.88 0.627 ***
TC* 2.38 0.025 1.67 0.195 1.25 0.416 1.66 0.086
NTC* 3.86 0.002 2.36 0.022 3.19 < 0.001 3.58 < 0.001
Sex 1.13 NS – – 1.30 0.037 – –
Age 50–59** 1.57 0.096 – – 1.49 NS 1.70 0.093
Age 60–69** 1.26 NS – – 2.66 < 0.001 2.81 < 0.001
Age > 70** 1.50 NS – – 6.13 < 0.001 6.11 < 0.001
Heart Failure 1.54 0.020 – – 1.82 < 0.001 1.43 0.010
AMI 1.40 NS – – 1.80 < 0.001 – –
Vascular 1.11 NS – – 1.71 < 0.001 – –
CNS disease 1.11 NS – – 1.43 0.008 – –
COPD 1.07 NS – – 1.25 NS – –
Collagenosis 1.98 0.003 1.58 0.050 0.78 NS – –
Peptic ulcer 2.00 < 0.001 1.73 0.005 1.43 0.017 – –
Liver disease 1.94 0.007 1.82 0.021 1.39 NS 2.23 < 0.001
Cancer 1.62 0.009 1.36 0.115 2.30 < 0.001 1.64 < 0.001
Diabetes 1.44 0.019 1.46 0.024 0.97 NS – –
Gram pos 0.84 NS – – 0.68 0.003 0.80 0.100
AMI acute myocardial infarction, CNS central nerve system, COPD chronic obstructive pulmonary disease, HD hemodialysis, AVF arteriovenous fistula, TC tunneled
catheter, NTC non-tunneled catheter, NS not significant, HR hazard ratio, CI confidence interval
*Analyzed as a four-leveled variable with peritoneal dialysis as reference
**Analyzed as a four-leveled variable with ‘age < 50 years’ as reference
***Included in the model as the overall P-value for the four-leveled variable was < 0.15
- did not meet the significance levels for final assessments in the fitted models
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in the post BSI population, only patients treated with
NTCs were significantly associated with an increased
risk of post BSI mortality and subsequent BSI episodes.
This could arguably be explained by lack of statistical
power judged by the relatively wide confidence intervals.
However, it appears plausible that BSI itself temporarily
outweighs other risk factors of death and infection
associated with dialysis and vascular access, which
would explain the lack of difference between AVF and
TC relative to PD. In this regard, a previous study
showed a comparable 30-day survival after BSI between
patients receiving HD and a matched group of popula-
tion controls, notwithstanding that the risk of BSI was
25 times greater with the HD patients [5]. Interestingly,
the otherwise markedly increased risk of death and
infection associated with NTCs somewhat declined in
the post BSI analyses. NTCs are mainly used use for a
shorter time and typically in acute settings, which
indeed has influenced on the risk of both death and
infection. This is supported by our baseline analyses
where a 60-day qualifying period reduced the overall
risk of mortality and BSI, hereby highlighting a signifi-
cant increased risk of these outcomes in patients initiat-
ing acute dialyses. However, due to the relatively short
usage time of NTCs and as these catheters usually are
renewed or removed in favor of other more sustainable
access types [27], NTCs may predict access change or
renewal in the setting of an ongoing BSI, which is
favorable in treatment of a severe catheter-related
infections, in which case antibiotics alone seem to be
inferior [28]. Conversely, one may be more reluctant to
remove TCs as compared to NCTs, which may increase
the risk of subsequent infections [29, 30], especially
with antibiotic resistant and biofilm-producing micro-
organisms which, in the current study, were more
frequently isolated in patients with more than two epi-
sodes of BSI. In this regard, TCs were also associated
with an increased risk of post BSI mortality and subse-
quent BSI as compared to AVF. Finally, there was a
trend towards an overall better outcome with AVF in
terms of post BSI mortality, and the risk of subsequent
BSIs was comparable to that of PD. This was further
supported by a significantly better outcome among
patients who changed their vascular access to an AVF
after first time BSI. Consequently, these results may in
part explain the lack of difference between PD and AVF
on all-cause mortality, notwithstanding an increased risk
of first-time BSI with the latter, as an increased risk of
first-time BSI associated with AVF relative to PD,
putatively is counter balanced by an actual reduced risk of
subsequent BSI and death with AVF, as compared to
catheter-based solutions including PD.
While the vascular access type was the only predictor
of first-time BSI in our main analysis, advanced
comorbidity was additionally associated with subsequent
BSI. In this regard, as the risk estimates associated with
vascular access types tends to be weakened in context of
a recent BSI, it appears plausible that the effect of other
risk predictors reach a higher statistical weight in the
model. These considerations may also apply for the fit-
ted statistical model, in which all the included elements
of the modified comorbidity index were assessed, and
where only diabetes and liver disease came out signifi-
cant in the analyses of first-time BSI; whereas collage-
noses, peptic ulcer, liver disease and diabetes were found
correlated with increased risk of subsequent BSI. To our
knowledge, risk factors associated with subsequent BSI
have not previously been investigated; however, there are
several studies to support the association between dia-
betes [8, 12, 15, 31–33] and low plasma albumin [12, 15,
31, 34–39], and the risk of infections, in which the latter
risk factor in part may be interpreted as a surrogate
marker of liver disease [40, 41]. Also, in concordance
with previous findings, advanced comorbidity and age
was associated with all-cause mortality; and as a novel
finding, this association remained significant after
first-time BSI. However, while all the analyzed possible
risk predictors except for sex were significantly associ-
ated with all-cause mortality in the fitted statistical
model, only age, heart failure, liver disease, and cancer
was associated with an increased risk of post BSI mortal-
ity. There are several causal explanations for death in a
cohort of patients on dialysis apart from BSI, in which
cardiovascular disease are the most frequent [3]. Also,
the applied comorbidity index was based on CCI, which
originally was verified to predict the one-year mortality
in patients with several co-occurring comorbidities [42].
Accordingly, we expected the included comorbidities to
be associated with all-cause mortality in the fitted model,
whereas, it appears plausible that only some of these came
out significant in analyses of post BSI death, as BSI itself is
strongly correlated with death and other potential risk
factors may not contribute further to the equation.
Conclusions
The current study presents novel data on the risk of
subsequent BSI and post BSI mortality to support a
decline in difference between PD and HD vascular
access modalities in the period after first-time BSI;
however, there was a persistently marked increased risk
of both outcomes with NTC. Furthermore, we suggest
that patients with an AVF have a favorable prognosis
after first-time BSI in terms post BSI mortality and
subsequent BSI in relation to any other analyzed vascu-
lar access type, and that AVF at least is as safe as PD.
Finally, although a CCI-based comorbidity index may
predict the risk of subsequent BSI as well as post BSI
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mortality among dialysis patients, only some of the vari-
ables contained in the index were found to be successful
risk predictors of these outcomes when analyzed in a
fitted statistical model. Further studies on the risk and
risk factors of post BSI mortality with explicit focus on
RRT and vascular access type are warranted.
Limitations
Despite adjustment for some but not all factors
known to influence risk of BSI and mortality among
patients receiving dialysis, residual confounding is in-
herent to observational studies and epidemiological
associations do not per se represent causal relation-
ships. Furthermore, results might have been affected
by limited sensitivity of the diagnostic codes by which
these risk factors were defined, and confounding may
have been introduced by the unequal distribution of
baseline parameters, although most of these were
accounted for in the Cox analyses. In this regard, one
central limitation to the current study was the lack of
information regarding the specific infectious focus
preceding a positive blood culture, as not all the in-
cluded BSIs were caused by dialysis related attributes.
Hence, some BSIs may have been initiated by infec-
tions (e.g. pneumonia or urinary tract infections),
which were not directly associated with a specific vas-
cular access or dialysis modality, however, may have
been driven by traits, such as advanced comorbidity
or frailty, not accounted for in the statistical models.
Nonetheless, confounding introduced by this is puta-
tively negligible, as sensitivity analyses in the current
study that exclusively included BSIs caused by S. aureus,
which is the most frequently isolated microorganism in
blood cultures from patients receiving HD, consistently
confirmed our main results. Moreover, as the risk of
BSI recently was found to be 28 times greater in pa-
tients receiving HD than in a matched population with-
out kidney disease [5], most of the BSIs among patients
receiving HD is putatively related to their vascular ac-
cess and frequent breaches of the natural skin barrier.
Changes from one blood access modality to another
were derived from the National Patient Registry, which
contains data of all operations. Another major limita-
tion in this study was that while registration of AVFs
putatively is exhaustive as the respective surgical
departments in part are financed through their listing
of procedure codes, registration of change from one
catheter type to another may have been underreported,
as this often is done in an acute setting, especially
regarding NTCs. Nonetheless, we tried to correct for
this putative lack of registration by censoring patients
who were registered with a NTC for more than 3
months, which in the worst case would underestimate
the risk of NTCs.
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